๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
DrugGlofitamab
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
Grit Biotechnology
Phase EARLY_PHASE1
28
Zhengzhou, Tianjin
2025-09-26
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT07012798Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-09-25
Not yet open
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
NCT07141095Infections, Cytomegalovirus
DrugMaribavir
Institute of Hematology & Blood Diseases Hospital, China
Observational
17
Tianjin
2025-09-25
Recruiting
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT07136142Malignant Solid Tumor
DrugFH-006
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
150
Shanghai, Tianjin
2025-09-23
Recruiting
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
NCT07232290Polycythemia Vera (PV)
DrugFlonoltinib
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
60
Tianjin
2025-09-23
Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07179783Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
DrugsTagitanlimab·Sac-TMT·Sacituzumab tirumotecan
Tianjin Medical University Second Hospital
Phase 2
28
Tianjin
2025-09-22
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Not yet open
Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
NCT07186088Myopia
Ruihua Wei
Not applicable
30
Tianjin
2025-09-20
Not yet open
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
NCT07179445NSCLC
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2025-09-20
Recruiting
Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy
NCT07160036Myopia
Ruihua Wei
Not applicable
180
Tianjin
2025-09-20
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
NCT07114315Pancreatic Cancer
DrugsAK130·Bevacizumab
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067Relapsed/Refractory Multiple Myeloma(MM)
Nanjing Legend Biotech Co.
Not applicable
35
Beijing, Tianjin, Wuhan
2025-09-16
Recruiting
Effects of Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD) on Memory and Cognitive Function in Adults With Sleep Deprivation: A Proof-of-Concept Study
NCT07084701Sleep Deprivation
Tao Liu
Not applicable
30
Tianjin
2025-09-15
Not yet open
Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)
NCT07188909Acute Graft-Versus-Host Disease
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
10
Tianjin
2025-09-15
Recruiting
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
NCT07018050Relapsed or Refractory Multiple Myeloma
DrugsQLS32015·Bortezomib·Pomalidomide·Daratumumab
Qilu Pharmaceutical Co., Ltd.
Phase 2
160
Tianjin
2025-09-12
Not yet open
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
NCT07157306Hepatocellular Carcinoma
DrugGecacitinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2025-09-10
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
DrugsMitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Active, closed
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT07184840Neuromyelitis Optica Spectrum Disorder Attack
DrugsIVMP·Methylprednisolone
Tianjin Medical University General Hospital
Phase 2
110
Tianjin
2025-09-09
Recruiting
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT07139873Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsDZD8586·Idelalisib·Bendamustine·Rituximab
Dizal Pharmaceuticals
Phase 3
250
Nanjing, Tianjin
2025-09-08
Recruiting
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
NCT07038629Esophageal Cancer
DrugsIparomlimab·S1
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2025-09-08
Recruiting
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
NCT07743112Acute Myeloid Leukemia
DrugsAzacitidine·Venetoclax
Maxinovel Pty., Ltd.
Phase 2
43
Tianjin
2025-09-05
Recruiting
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
NCT07165769Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli๏ผŒSBLPN
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
47
Tianjin
2025-09-04
Recruiting
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
NCT07151690Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-09-04
Recruiting
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
NCT07234110Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
18
Tianjin
2025-09-03
Recruiting
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
NCT06880380HIV Infected Individuals, HIV
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
3
Tianjin
2025-09-01
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
DrugChidamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Not yet open
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT07153965Triple Negative Breast Cancer (TNBC), PD-L1 Positive
DrugsTagitanlimab·Sacituzumab tirumotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
47
Tianjin
2025-09-01
Recruiting
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
NCT07776821Uterine Cervical Neoplasms
DrugEnlonstobart
Tianjin Medical University Cancer Institute and Hospital
Phase 4
31
Tianjin
2025-09-01
Recruiting
Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)
NCT07321210Upper Tract Urothelial Carcinoma, Lymph Node Dissection
Tianjin Medical University Second Hospital
Not applicable
150
Tianjin
2025-09-01
Recruiting
Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC)
NCT07321197Renal Cell Carcinoma (Kidney Cancer)
Tianjin Medical University Second Hospital
Not applicable
220
Tianjin
2025-09-01
Recruiting
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
NCT07130578Bladder Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Not yet open
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT07181239Multiple Myeloma (MM)
Keymed Biosciences Co.Ltd
Phase 3
280
Tianjin
2025-09
Recruiting
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
NCT07132684AML, Adult
DrugsCytarabine·Azacitidine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
240
Tianjin
2025-08-31
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsUtidelone·Oxaliplatin·Capecitabine
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT07283796NHL
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
110
Tianjin
2025-08-28
Recruiting
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
NCT07115667Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-08-25
Recruiting
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
NCT07099274HCC
DrugLparomlimab and Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2025-08-22
Not yet open
Effect of Early Lifestyle Intervention on Perinatal Outcomes in High-risk Women for Gestational Hyperglycemia
NCT07141173GDM
Tianjin Central Hospital of Gynecology Obstetrics
Not applicable
604
Tianjin
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsASP5541·Prednisolone·Abiraterone acetate·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Yangzhou, Tianjin, Hangzhou, Huaian, Shanghai
2025-08-19
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
Fuzhou, Wuhan, Shanghai, Tianjin
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
NCT07183150Gastric Cancer (GC), No.4sb
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-08-18
By invitation
A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07657052Paroxysmal Nocturnal Hemoglobinuria
DrugXH-S003
S-INFINITY Pharmaceuticals Co., Ltd
Not applicable
26
Tianjin
2025-08-15
Not yet open
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
NCT07139470Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
59
Tianjin
2025-08-15
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugCadonilimab
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Not yet open
Prognostic Model for MASLD Related Cirrhosis
NCT07082751Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Beijing Friendship Hospital
Observational
228
Beijing, Tianjin
2025-08-13
Recruiting
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Tianjin
2025-08-13
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Hangzhou, Tianjin, Wuhan
2025-08-12
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684Multiple Myeloma, Plasma Cell Leukemia
DrugsGPRC5D/CD3 BiTEs·Bcma Car-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-10
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
NCT07106671CRS - Cytokine Release Syndrome, Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-10
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710Multiple Myeloma, Newly Diagnosed
DrugsGPRC5D/CD3 BiTEs·Bcma Car-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08-10
Recruiting
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
NCT07106736Multiple Myeloma, Newly Diagnosed
DrugsGPRC5D/CD3 BiTEs·Bcma Car-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2025-08-10
Not yet open
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NCT07115654POEMS Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2025-08-10
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Not yet open
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
NCT07032116Diabetic Kidney Disease (DKD)
Liu Hongfang
Observational
4,472
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Recruiting
Assessment of DOT Spectacles in Chinese Children Extension
NCT07008001Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Not yet open
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
NCT07034807Diabetic Kidney Disease (DKD)
Liu Hongfang
Not applicable
228
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Not yet open
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
NCT07114432Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital
Phase 1
19
Tianjin
2025-08
Recruiting
Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy
NCT07127289Prolonged Cytopenia Following CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08
Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
NCT07063225Chemotherapy-induced Thrombocytopenia, Romiplostim N01
DrugRomiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-08
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199Immune Thrombocytopenia, Treatment
DrugDaratumumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Recruiting
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
NCT07172386Renal Cell Carcinoma (RCC)
Tianjin Medical University Second Hospital
Phase 2
40
Tianjin
2025-07-31
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
DrugPirtobrutinib
Eli Lilly and Company
Phase 1/2
68
Guangzhou, Jinan, Tianjin, Wuhan
2025-07-30
Recruiting
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
NCT07039578Primary Light-Chain Amyloidosis
Keymed Biosciences Co.Ltd
Phase 2
90
Beijing, Tianjin
2025-07-25
Recruiting
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease๏ผˆNAFLD๏ผ‰
NCT07128797NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)
Tasly Biopharmaceuticals Co., Ltd.
Phase 1
32
Beijing, Guangzhou, Datong, Tianjin, Wenzhou
2025-07-24
Recruiting
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
NCT07232459Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
Tianjin Medical University
Observational
25
Hefei, Qingdao, Tianjin
2025-07-21
Not yet open
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
NCT07078721Aplastic Anemia Idiopathic
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
11
Tianjin
2025-07-20
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
DrugsValproate·KarXT
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Not yet open
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07068906B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
27
Tianjin
2025-07-15
Recruiting
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
NCT07070349Patients With Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
48
Tianjin
2025-07-10
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
NCT07086300Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors, Electroacupuncture
Kong Fanming
Not applicable
120
Tianjin
2025-07-08
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
DrugsPD-1 inhibitior·Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
DrugsNab-paclitaxel·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
By invitation
Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
NCT07409298CDK4/6 Inhibitors, Depression Anxiety Disorder, Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
300
Tianjin
2025-07-05
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
NCT07312188Relapsed or Refractory Multiple Myeloma
DrugF182112
Shandong New Time Pharmaceutical Co., LTD
Phase 2
90
Tianjin
2025-07-02
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Not yet open
BR Combined With OR in Treatment-naรฏve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
DrugBR
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Not yet open
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
NCT07005583Triple-Negative Breast Cancer (TNBC)
DrugsOlaparib·Iparomlimab and Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2025-06-30
Recruiting
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
NCT07106749Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07153068T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
12
Tianjin
2025-06-28
Recruiting
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
NCT07169487Cytokine Release Syndrome, ICANS
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2025-06-28
Recruiting
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07109518Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers
NCT07091825Myopia
Avizor SA
Not applicable
152
Beijing, Tianjin
2025-06-27
Recruiting
A Study of CT0596 in Plasma Cell Leukemia
NCT06988059Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
27
Tianjin
2025-06-25
Active, closed
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408Chronic Graft-versus-host-disease
DrugINCA034176
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
DrugsEntinostat·Pyrotinib
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Not yet open
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
NCT07034508DLBCL - Diffuse Large B Cell Lymphoma
DrugsPolatuzumab Vedotin·Doxorubicin·Prednisone·Rituximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Tianjin
2025-06-20
Recruiting
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
NCT06622694Severe Aplastic Anemia, Relapse, Refractory, CAR T-cell Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2025-06-19
Recruiting
Universal Chimeric Antigen Receptor T-Cell ๏ผˆUCAR T-cell๏ผ‰ Therapy Targeting CD19/B Cell Maturation Antigen ๏ผˆCD19/BCMA๏ผ‰ in Patients With r/r Neurological Autoimmune Diseases
NCT06939166Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Tianjin Huanhu Hospital
Phase EARLY_PHASE1
12
Tianjin
2025-06-17
Recruiting
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
NCT07012109Polycythemia Vera
BeBetter Med Inc
Phase 1
90
Tianjin
2025-06-17
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Recruiting
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
NCT07106723CD7 Positive, T - Cell Lymphoma
DrugASCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-06-01
Recruiting
Real-world Studies of CDK4/6 Inhibitors
NCT07407439Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
245
Tianjin
2025-06-01
Recruiting
Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases
NCT07801274Spinal Metastases, Metastatic Epidural Spinal Cord Compression, Spinal Cord Compression
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2025-06-01
Not yet open
Optimal Timing of Hepatitis B Vaccination After Transplants
NCT06888479Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
DrugHepatitis B vaccine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,500
Tianjin
2025-06-01
Rows per page Showing 301–400 of 940
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.